![Atea Pharmaceuticals, Inc. logo](/logos/AVIR.webp)
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
Overview | Financials
Company Name | Atea Pharmaceuticals, Inc. |
Symbol | AVIR |
Currency | USD |
Price | 3.6 |
Market Cap | 303,919,200 |
Dividend Yield | 0% |
52-week-range | 2.765 - 4.6 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jean-Pierre Sommadossi Ph.D. |
Website | https://ateapharma.com |
An error occurred while fetching data.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD